金城医药：子公司“普罗雌烯乳膏”获得韩国药品进口许可

Core Viewpoint - Jin Cheng Pharmaceutical's subsidiary, Beijing Jin Cheng Tai Er Pharmaceutical Co., Ltd., has received an import license for Progestin Cream from the Korean Ministry of Food and Drug Safety, marking a significant regulatory achievement for the company in the international market [1] Company Summary - Jin Cheng Tai Er has obtained the import license for Progestin Cream, which is the only marketed estrogen with strict local action, used for treating atrophic changes in the vulva, vestibule, and vaginal area, as well as associated symptoms such as discomfort, itching, burning, and dryness [1] - The product addresses conditions related to Genitourinary Syndrome of Menopause (GSM), which occurs due to decreased estrogen and other hormone levels in women during and after menopause [1] Industry Summary - Local estrogen application is recommended as the first-line treatment for GSM according to domestic and international guidelines, with Progestin Cream being one of the options available [1] - The global sales figures for Progestin formulations are projected to be $78.10 million in 2022, $94.34 million in 2023, and $103.86 million in 2024, indicating a growing market for this therapeutic category [1]